Physician profile
Mona Romezi
NPI 1568773737
$3,636.72
in general payments reported to CMS, 2019-2025
34 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $369 · 2021: $570 · 2022: $857 · 2023: $493 · 2024: $575 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $358.47 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Pfizer INC. | $329.43 | 2019-2024 | |
| Therapeuticsmd, INC. | $328.13 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $322.89 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $312.93 | 2021-2024 | |
| Exeltis, USA INC. | $280.13 | 2020-2025 | Slynd |
| Evofem Biosciences, INC. | $157.20 | 2021-2025 | Phexxi, Solosec, Phexx |
| Sumitomo Pharma America, INC. | $140.08 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $138.80 | 2019-2025 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Astellas Pharma US INC | $134.97 | 2024-2025 | Veozah |
| Myovant Sciences INC. | $123.26 | 2021-2022 | |
| Millicent US INC | $118.93 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Novo Nordisk INC | $99.12 | 2023-2025 | Wegovy |
| Sage Therapeutics, LLC | $84.13 | 2024-2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $81.28 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $73.50 | 2022 | |
| Amag Pharmaceuticals, INC. | $70.57 | 2019-2020 | |
| Organon LLC | $63.44 | 2022-2024 | Nexplanon |
| Mylan Pharmaceuticals INC. | $52.82 | 2019-2021 | |
| Coopersurgical, INC. | $50.17 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Ethicon US, LLC | $47.05 | 2019-2022 | |
| Shield Therapeutics INC | $32.36 | 2022-2024 | |
| Exact Sciences Corporation | $31.42 | 2024 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $30.91 | 2021-2022 | |
| Avion Pharmaceuticals | $26.52 | 2020 | |
| Gilead Sciences, INC. | $23.87 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $19.13 | 2025 | Exparel |
| Smith+Nephew, INC. | $18.35 | 2019 | |
| Allergan, INC. | $17.04 | 2019 | |
| Scynexis, INC. | $16.45 | 2022 | |
| Aspira Women'S Health INC | $14.66 | 2024 | Ova1 |
| Currax Pharmaceuticals LLC | $14.16 | 2022 | |
| Medicem INC. | $12.86 | 2020 | |
| Meditrina | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Romezi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.